VNDA - Vanda Pharmaceuticals Inc.

-

$undefined

N/A

(N/A)

Vanda Pharmaceuticals Inc. NasdaqGM:VNDA Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Location: 2200 Pennsylvania Avenue NW, Washington, DC, 20037, United States | Website: https://www.vandapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-70.44M

Cash

340.9M

Avg Qtr Burn

-14.12M

Short % of Float

9.28%

Insider Ownership

6.66%

Institutional Own.

77.66%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HETLIOZ® (tasimelteon) Details
SMS (Smith-Magenis Syndrome)

Approved

Quarterly sales

Fanapt® (iloperidone) Details
Mental health, Bipolar depression, Bipolar disease

Approved

Quarterly sales

Fanapt® (iloperidone) Details
Schizophrenia and PDP (Parkinson's disease psychosis)

Approved

Quarterly sales

HETLIOZ® (tasimelteon) Details
Non-24-Hour Sleep-Wake Disorder (Non-24)

Approved

Quarterly sales

Approved

Quarterly sales

Bysanti™ (milsaperidone) Details
Schizophrenia, Mental health, Bipolar disease

PDUFA

Approval decision

sNDA

Resubmission

sNDA

FDA meeting

Tradipitant Details
Motion sickness

NDA

Acceptance for review

NDA

Resubmission

Bysanti™ (milsaperidone) Details
Mental Health, Major depressive disorder

Phase 3

Data readout

VQW-765 Details
Social Anxiety Disorder

Phase 3

Initiation

VSJ-110 Details
Dry eye disease

Phase 2

Data readout

Trichostatin A (VTR-297) Details
Onychomycosis, Fungal infections

Phase 1

Data readout

VCA-894A Details
Charcot-Marie-Tooth disease, axonal, type 2S , Neuropathy

Phase 1

Initiation

Failed

Discontinued

Tradipitant Details
Atopic pruritus , Atopic dermatitis

Failed

Discontinued

Trichostatin A (VTR-297) Details
Leukemia, Multiple myeloma, Lymphoma

Failed

Discontinued